1 – 2 of 2
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2022
-
Mark
Efficacy and safety of larotrectinib in TRK fusion-positive primary central nervous system tumors
(
- Contribution to journal › Article
- 2021
-
Mark
Discovery of a rare GKAP1-NTRK2 fusion in a pediatric low-grade glioma, leading to targeted treatment with TRK-inhibitor larotrectinib
(
- Contribution to journal › Article